ClinicalTrials.gov
public full text
Public Domain
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Intestinal Carcinoma#800588
- Association between serum CEA levels and ctDNA-detected Epidermal Growth Factor Receptor mutations in lung adenocarcinoma#456613
- Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy#1163530
- New prognostic and predictive scoring systems for colorectal cancer liver metastases.#67481
- Fecal DNA Methylation Test for Colorectal Cancer Screening#917100
Record · ID 836824
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive